BlackRock Fund Advisors has recently announced that it has increased stake in Vir Biotechnology Inc. (NASDAQ:VIR) by 5.53%. After grabbing 12.18 million shares, the institutional investor is now in possession of 0.64 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 9.18% having worth around $267.66 million. Moreover, The Vanguard Group, Inc. increased its share by 1.73 million to have a control over 9.81 million shares. And Temasek Holdings Pte Ltd. raised its holdings to 0.43 million shares by acquiring 6.04 million shares or 4.55% of the stake.
Vir Biotechnology Inc. (VIR) concluded trading on 11/23/22 at a closing price of $27.25, with 0.48 million shares of worth about $13.0 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 15.17% during that period and on Wednesday the price saw a loss of about -0.58%. Currently the company’s common shares owned by public are about 132.73M shares, out of which, 115.10M shares are available for trading.
Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $67.00 and could fall to a lowest price of $18.00. The stock’s current price level is 44.95% above of average price target set by the analysts, while a rise to estimated low would result in loss of -51.39% for the stock. However, touching the estimated high of $67.00 would mean a gain of 59.33% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 186 times over the past 12 months. They bought 1,522,385 shares in 94 of the transactions. In 92 selling transactions, insiders dumped 11,339,215 shares.
iShares Core S&P Small Cap ETF, Scottish Mortgage Investment Trus, and SPDR S&P Biotech ETF are the top 3 mutual funds which are holding stakes in Vir Biotechnology Inc. iShares Core S&P Small Cap ETF is currently holding 5.6 million shares of worth totaling $123.11 million. The company recently came buying 3904.0 shares which brought its stake up to 4.22% of the company’s outstanding shares. Scottish Mortgage Investment Trus bought 3730.0 shares, after which its hold over company’s outstanding shares expand to 2.84%, leaving 3.76 million shares with the mutual fund that have a worth of about $82.75 million. SPDR S&P Biotech ETF, after buying 3.65 million shares, have now control over 2.75% of the stake in the company. It holds 20200.0 shares of worth $80.28 million.
Vir Biotechnology Inc. (NASDAQ: VIR) started trading at $27.23, below -$0.18 from concluding price of the previous day. However, the stock later moved at a day high price of 27.56, or with a loss of -0.58%. Stock saw a price change of -0.22% in past 5 days and over the past one month there was a price change of 24.32%. Year-to-date (YTD), VIR shares are showing a performance of -34.92% which decreased to -12.01% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $18.05 but also hit the highest price of $58.00 during that period. The average intraday trading volume for Vir Biotechnology Inc. shares is 1.03 million. The stock is currently trading 7.75% above its 20-day simple moving average (SMA20), while that difference is up 22.12% for SMA50 and it goes to 10.91% higher than SMA200.
BlackRock Fund Advisors acquired 12.18 million shares of Vir Biotechnology Inc. having value of about $267.66 million. Data submitted at the U.S SEC by BlackRock Fund Advisors revealed that the firm now holds 0.64 million shares in the company valued at close to $17401250.5, or have control over 5.53% stake in the company. Vir Biotechnology Inc. (NASDAQ: VIR) currently have 132.73M outstanding shares and institutions hold larger chunk of about 76.10% of that. Holding of mutual funds in the company is about 30.96% while other institutional holders and individual stake holders have control over 33.72% and 18.30% of the stake respectively.
The stock has a current market capitalization of $3.66B. PE ratio of stock for trailing 12 months is 3.21, while it has posted earnings per share of $8.50 in the same period. Its PEG reads 0.46 and has Quick Ratio of 7.80 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for VIR, volatility over the week remained 2.94% while standing at 4.62% over the month.
Analysts are in expectations that Vir Biotechnology Inc. (VIR) stock would likely to be making an EPS of -$0.18 in the current quarter, while forecast for next quarter EPS is -$0.75 and it is -$3.3 for next year. For the current quarter EPS, analysts have given the company a lowest target -$1.19 which is $1.78 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $0.82 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 258.00% while it is estimated to decrease by -167.30% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by SVB Leerink on September 14, 2022 offering an Outperform rating for the stock and assigned a target price of $40 to it. Coverage by Morgan Stanley stated Vir Biotechnology Inc. (VIR) stock as an Underweight in their note to investors on September 09, 2022, suggesting a price target of $15 for the stock. On March 03, 2022, Robert W. Baird Upgrade their recommendations, while on December 21, 2021, Robert W. Baird Downgrade their ratings for the stock with a price target of $36. Stock get a Neutral rating from JP Morgan on October 25, 2021.